scPharmaceuticals (SCPH) Competitors $2.19 +0.04 (+1.86%) Closing price 04/9/2025 04:00 PM EasternExtended Trading$2.19 0.00 (0.00%) As of 04/9/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SCPH vs. OPT, URGN, SAGE, ARVN, MAZE, PRTC, TYRA, SION, AKBA, and RLAYShould you be buying scPharmaceuticals stock or one of its competitors? The main competitors of scPharmaceuticals include Opthea (OPT), UroGen Pharma (URGN), Sage Therapeutics (SAGE), Arvinas (ARVN), Maze Therapeutics (MAZE), PureTech Health (PRTC), Tyra Biosciences (TYRA), Sionna Therapeutics (SION), Akebia Therapeutics (AKBA), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry. scPharmaceuticals vs. Opthea UroGen Pharma Sage Therapeutics Arvinas Maze Therapeutics PureTech Health Tyra Biosciences Sionna Therapeutics Akebia Therapeutics Relay Therapeutics scPharmaceuticals (NASDAQ:SCPH) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends. Do analysts prefer SCPH or OPT? scPharmaceuticals currently has a consensus target price of $14.00, suggesting a potential upside of 539.27%. Opthea has a consensus target price of $1.33, suggesting a potential downside of 60.90%. Given scPharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe scPharmaceuticals is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score scPharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17 Do institutionals & insiders believe in SCPH or OPT? 89.5% of scPharmaceuticals shares are owned by institutional investors. Comparatively, 56.0% of Opthea shares are owned by institutional investors. 5.5% of scPharmaceuticals shares are owned by company insiders. Comparatively, 3.2% of Opthea shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is SCPH or OPT more profitable? Opthea has a net margin of 0.00% compared to scPharmaceuticals' net margin of -264.60%. Opthea's return on equity of 0.00% beat scPharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets scPharmaceuticals-264.60% -244.93% -68.56% Opthea N/A N/A N/A Does the MarketBeat Community believe in SCPH or OPT? scPharmaceuticals received 144 more outperform votes than Opthea when rated by MarketBeat users. Likewise, 67.08% of users gave scPharmaceuticals an outperform vote while only 48.72% of users gave Opthea an outperform vote. CompanyUnderperformOutperformscPharmaceuticalsOutperform Votes16367.08% Underperform Votes8032.92% OptheaOutperform Votes1948.72% Underperform Votes2051.28% Which has more volatility & risk, SCPH or OPT? scPharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Opthea has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Which has preferable earnings & valuation, SCPH or OPT? scPharmaceuticals has higher revenue and earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioscPharmaceuticals$36.33M3.03-$54.81M-$1.90-1.15Opthea$87.67K5,986.77-$220.24MN/AN/A Does the media refer more to SCPH or OPT? In the previous week, Opthea had 6 more articles in the media than scPharmaceuticals. MarketBeat recorded 7 mentions for Opthea and 1 mentions for scPharmaceuticals. Opthea's average media sentiment score of 0.08 beat scPharmaceuticals' score of 0.00 indicating that Opthea is being referred to more favorably in the news media. Company Overall Sentiment scPharmaceuticals Neutral Opthea Neutral SummaryscPharmaceuticals beats Opthea on 9 of the 17 factors compared between the two stocks. Remove Ads Get scPharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPH vs. The Competition Export to ExcelMetricscPharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$110.12M$6.27B$5.28B$7.60BDividend YieldN/A2.94%5.34%4.27%P/E Ratio-1.156.8322.0118.06Price / Sales3.03200.79349.0590.67Price / CashN/A65.6738.1534.64Price / Book2.115.646.243.95Net Income-$54.81M$140.88M$3.19B$247.18M7 Day Performance-4.78%0.21%-1.36%0.06%1 Month Performance-24.22%-10.03%-0.47%-5.03%1 Year Performance-54.18%-17.16%4.87%-3.63% scPharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPHscPharmaceuticals3.3441 of 5 stars$2.19+1.9%$14.00+539.3%-56.4%$110.12M$36.33M-1.1530Gap DownHigh Trading VolumeOPTOpthea0.8304 of 5 stars$3.41+7.2%$1.33-60.9%-16.6%$524.84M$87,666.000.008Gap UpURGNUroGen Pharma3.5667 of 5 stars$11.06-1.3%$38.20+245.4%-24.5%$509.80M$90.40M-3.51200Positive NewsGap DownSAGESage Therapeutics4.1279 of 5 stars$7.95-4.0%$8.81+10.8%-58.1%$488.77M$41.24M-1.21690Gap DownARVNArvinas3.522 of 5 stars$7.02-7.5%$35.50+405.7%-82.3%$482.78M$263.40M-2.53420Analyst ForecastNews CoverageGap DownHigh Trading VolumeMAZEMaze TherapeuticsN/A$11.01-3.6%$25.67+133.1%N/A$481.99M$167.50M0.00121PRTCPureTech Health1.4595 of 5 stars$19.78+2.3%$45.00+127.5%-45.9%$475.10M$3.33M0.00100News CoverageGap DownTYRATyra Biosciences1.8396 of 5 stars$9.30-4.8%$30.83+231.5%-53.5%$470.61MN/A-5.7820SIONSionna TherapeuticsN/A$10.46-9.5%$38.50+268.1%N/A$461.54MN/A0.0035Gap DownAKBAAkebia Therapeutics3.5739 of 5 stars$1.92+0.5%$6.75+251.6%+10.4%$453.56M$160.18M-8.35430RLAYRelay Therapeutics2.1304 of 5 stars$2.62-3.7%$19.80+655.7%-68.5%$444.15M$10.01M-1.00330 Remove Ads Related Companies and Tools Related Companies Opthea Alternatives UroGen Pharma Alternatives Sage Therapeutics Alternatives Arvinas Alternatives Maze Therapeutics Alternatives PureTech Health Alternatives Tyra Biosciences Alternatives Sionna Therapeutics Alternatives Akebia Therapeutics Alternatives Relay Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCPH) was last updated on 4/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s policies mean HUGE income for investorsThanks to a Trump win… Investors have a HUGE opportunity at new income. The floodgates for U.S. oil prod...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWhy crypto may be the best way to play this chaotic market …Wall Street is in chaos … Over $6 trillion was wiped … in just two days. But something else was happenin...Weiss Ratings | SponsoredBITCOINYou're not going to believe this. There's a bizarre new way to make money from crypto... ...and it's not...Awesomely, LLC | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredUrgent: Tariff Traders — Read Before TomorrowURGENT: Trump's "Liberation Day" Ignites Trader's Paradise Wall Street legend Larry Benedict has spotted a ra...Brownstone Research | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share scPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SCPH Stock Free SCPH Stock Alerts